JP6219849B2 - 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド - Google Patents

発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド Download PDF

Info

Publication number
JP6219849B2
JP6219849B2 JP2014554791A JP2014554791A JP6219849B2 JP 6219849 B2 JP6219849 B2 JP 6219849B2 JP 2014554791 A JP2014554791 A JP 2014554791A JP 2014554791 A JP2014554791 A JP 2014554791A JP 6219849 B2 JP6219849 B2 JP 6219849B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
polynucleotide
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014554791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506179A (ja
JP2015506179A5 (enExample
Inventor
リー，ジョン，エイチ．
フェルメール，ダニエル，ダブリュ．
Original Assignee
サンフォード ヘルス
サンフォード ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード ヘルス, サンフォード ヘルス filed Critical サンフォード ヘルス
Publication of JP2015506179A publication Critical patent/JP2015506179A/ja
Publication of JP2015506179A5 publication Critical patent/JP2015506179A5/ja
Application granted granted Critical
Publication of JP6219849B2 publication Critical patent/JP6219849B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014554791A 2012-01-24 2013-01-23 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド Active JP6219849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590089P 2012-01-24 2012-01-24
US61/590,089 2012-01-24
PCT/US2013/022696 WO2013112549A1 (en) 2012-01-24 2013-01-23 Polynucleotides for treating oncogenic viral polypeptide positive tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017188121A Division JP6655051B2 (ja) 2012-01-24 2017-09-28 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド

Publications (3)

Publication Number Publication Date
JP2015506179A JP2015506179A (ja) 2015-03-02
JP2015506179A5 JP2015506179A5 (enExample) 2016-03-10
JP6219849B2 true JP6219849B2 (ja) 2017-10-25

Family

ID=48873849

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014554791A Active JP6219849B2 (ja) 2012-01-24 2013-01-23 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
JP2017188121A Active JP6655051B2 (ja) 2012-01-24 2017-09-28 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017188121A Active JP6655051B2 (ja) 2012-01-24 2017-09-28 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド

Country Status (10)

Country Link
US (3) US9492526B2 (enExample)
EP (2) EP3269387B1 (enExample)
JP (2) JP6219849B2 (enExample)
KR (1) KR102195196B1 (enExample)
CN (2) CN110042110A (enExample)
DK (1) DK2806889T3 (enExample)
ES (1) ES2646590T3 (enExample)
HK (1) HK1203833A1 (enExample)
IN (1) IN2014DN06118A (enExample)
WO (1) WO2013112549A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
JP7098330B2 (ja) 2015-06-10 2022-07-11 ホオキパ バイオテック ジーエムビーエイチ Ｈｐｖワクチン
ES2934698T3 (es) 2015-11-04 2023-02-24 Hookipa Biotech Gmbh Vacunas contra el virus de la hepatitis B
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
GB201605210D0 (en) * 2016-03-29 2016-05-11 Oxford Immunotec Ltd Assay
AU2017272356A1 (en) * 2016-06-03 2018-12-20 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases
CN106655327A (zh) * 2016-10-18 2017-05-10 云南中烟工业有限责任公司 一种压缩式充电装置
CN109891405B (zh) * 2016-11-11 2023-09-26 谷歌有限责任公司 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质
IL314393A (en) 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and uses of the same
CA3178325A1 (en) * 2020-05-25 2021-12-02 Soo Ok Kim Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein
KR102712588B1 (ko) * 2020-05-25 2024-10-02 (주)진매트릭스 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6864054B1 (en) * 1998-05-26 2005-03-08 Institute Of Molecular And Cell Biology Polypeptides from CREB binding protein and related protein p300 for use in transcriptional regulation
BR0314529A (pt) 2002-10-03 2005-08-09 Wyeth Corp Polipeptìdeos de papilomavìrus humano e composições imunogênicas
BRPI0810305A2 (pt) * 2007-05-15 2018-07-10 Transgene Sa "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
CA2760310A1 (en) 2009-04-28 2010-11-11 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途

Also Published As

Publication number Publication date
EP3269387A1 (en) 2018-01-17
EP3269387B1 (en) 2019-07-17
KR20140131929A (ko) 2014-11-14
US20150023996A1 (en) 2015-01-22
HK1203833A1 (en) 2015-11-06
CN110042110A (zh) 2019-07-23
EP2806889B1 (en) 2017-08-16
US20160376324A1 (en) 2016-12-29
US9492526B2 (en) 2016-11-15
IN2014DN06118A (enExample) 2015-08-14
CN104159607A (zh) 2014-11-19
ES2646590T3 (es) 2017-12-14
US9969779B2 (en) 2018-05-15
WO2013112549A1 (en) 2013-08-01
EP2806889A1 (en) 2014-12-03
JP2015506179A (ja) 2015-03-02
JP2018038405A (ja) 2018-03-15
EP2806889A4 (en) 2016-04-20
JP6655051B2 (ja) 2020-02-26
KR102195196B1 (ko) 2020-12-28
US20180237477A1 (en) 2018-08-23
DK2806889T3 (da) 2017-11-20

Similar Documents

Publication Publication Date Title
JP6219849B2 (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
JP6688535B2 (ja) ワクチン組成物
CN103998604B (zh) Hbv聚合酶突变体
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
US9707285B2 (en) Vaccination methods
JP2019505205A (ja) Ｈｂｖを処置するための手段及び方法
JP2015506704A (ja) 腫瘍関連異種抗原を発現するアデノウイルス
Singh et al. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial
JP2020527029A (ja) Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
JP2021506767A (ja) Ｂ型肝炎免疫化レジメン及び組成物
Broeckel et al. Vaccine-induced skewing of T cell responses protects against Chikungunya virus disease
US20240415951A1 (en) Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
JP2021506771A (ja) Ｂ型肝炎免疫化レジメン及び組成物
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
WO2024023135A1 (en) Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
JP2003321391A (ja) 組換えワクシニアウイルスを用いたｈｉｖワクチン
Zeon Patent Report

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160121

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170928

R150 Certificate of patent or registration of utility model

Ref document number: 6219849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250